glp 1 agonist trials GLP-1 receptor agonists are increasingly used to treat type 2 diabetes and obesity, and have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal. Read Discover How GLP-1 Trials Are

Rossing, P

Some case reports have revealed that Pso symptoms can deteriorate soon after patients start GLP-1RA therapy, which indicates that these medications may activate immune dysregulation instead of providing suppression in certain individuals [20]

#MOTSC #LongevityMedicine #MitochondrialHealth #MetabolicMedicine #EllieMD #FunctionalMedicine #ProviderPartnership #PrescriptionTherapy #IntegrativeMedicine To view or add a comment, sign in Anyone who has ever lost weight knows that keeping it off can often be more challenging than losing it in the first place

doi: 10.1016/j.peptides.2024.171271

In hypertension, GLP-1 attenuates the excitability of carotid body cells diminishing sympathetic activation, augments renal blood flow to promote natriuresis and diuresis as well as facilitates generation of nitric oxide in vascular smooth muscle cells

In fact, if GIP receptor agonists (GIP RA) are effective in stimulating insulin secretion and favoring peripheral glucose uptake, alone they are unable to influence body weight [17,163]